By the ZIVOLABS Medical Team · Updated April 2026 · 8 min read

GLP-1 medication occupies a rare position in medicine: it is one of the few treatments that meaningfully addresses two major chronic conditions simultaneously — Type 2 diabetes and obesity. And in the Indian context, where both conditions occur together with striking frequency, this makes it particularly significant.

Here is how GLP-1 medication works for diabetes, what results patients can expect, and why Indian doctors are increasingly making it a first-line recommendation.

The diabetes epidemic in India

India has the second-largest population of people with Type 2 diabetes in the world — over 100 million adults, with tens of millions more in the pre-diabetic range. The numbers continue to rise.

What makes the Indian situation distinct is that Type 2 diabetes here tends to develop at lower body weights than in Western populations, and at younger ages. An Indian adult with a BMI of 25 may already have meaningful insulin resistance — the biological root of Type 2 diabetes — while a European adult at the same BMI may not.

The overlap between diabetes and obesity in India is substantial. Most patients with Type 2 diabetes are also overweight or obese. And the weight makes the diabetes harder to control. The diabetes makes the weight harder to lose. GLP-1 medication addresses both simultaneously.

How GLP-1 medication works for Type 2 diabetes

Type 2 diabetes is a condition of impaired insulin function. Either the pancreas does not produce enough insulin, or the body's cells have become resistant to it — or both. The result is elevated blood glucose that, over years and decades, damages blood vessels, nerves, kidneys, eyes, and the heart.

GLP-1 receptor agonists address this through several complementary mechanisms:

Glucose-dependent insulin stimulation. Semaglutide stimulates the pancreatic beta cells to release insulin — but only when blood glucose is elevated. This is a critically important safety feature. Unlike sulfonylureas (older diabetes drugs), semaglutide does not trigger insulin release when blood sugar is already normal. This means it does not cause the dangerous hypoglycaemia (low blood sugar episodes) that are a common and serious risk with older diabetes medications.

Glucagon suppression. Glucagon is a hormone that tells the liver to release stored glucose into the bloodstream. In Type 2 diabetes, glucagon is often elevated — contributing to high fasting blood sugar. Semaglutide suppresses glucagon, reducing this background glucose release.

Slowed gastric emptying. By slowing the rate at which food moves from the stomach into the intestine, semaglutide blunts the sharp post-meal glucose spike. Blood sugar rises more gradually and to a lower peak after eating — which is exactly what diabetes management aims for.

Improved insulin sensitivity. As patients lose weight on semaglutide, their cells become more responsive to insulin. Less insulin is required to achieve the same glucose-lowering effect. In some patients who achieve substantial weight loss, this improvement in insulin sensitivity is dramatic.

What results can diabetic patients expect?

The clinical evidence is substantial. In the SUSTAIN trial programme — Novo Nordisk's landmark diabetes trials for semaglutide — the results across thousands of patients showed:

HbA1c reduction of 1.0–1.8 percentage points. HbA1c is the key measure of average blood glucose over three months. A reduction of 1–2 percentage points is clinically significant. To put this in context: a patient with HbA1c of 8.5% (poorly controlled diabetes) might reach 6.8–7.5% (well-controlled) on semaglutide without any other changes.

Weight loss of 4–6 kg on average in diabetic patients. Diabetic patients tend to lose somewhat less weight than non-diabetic patients on semaglutide — likely because some diabetes medications cause weight gain, and the metabolic environment is different. But even this level of weight loss meaningfully improves diabetes control.

Reduced cardiovascular risk. The SUSTAIN-6 cardiovascular outcome trial showed that semaglutide reduced the rate of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 26% compared to placebo in high-risk diabetic patients. This is not just sugar control — it is heart protection.

Can GLP-1 medication put diabetes into remission?

This is the question that has generated significant excitement in the medical community — and the answer is: yes, for some patients.

Diabetes remission is defined as achieving HbA1c below 6.5% without diabetes medication. It is most likely in patients who:

• Have had diabetes for a shorter duration (less than 5–10 years)

• Achieve substantial weight loss (typically 10–15% or more of body weight)

• Still have reasonable pancreatic function remaining

In the DiRECT trial (using a different approach — very low calorie diet), remission was achieved in around 46% of participants at one year with significant weight loss. GLP-1 medication, which produces comparable and more sustained weight loss, is now being studied specifically as a remission tool.

It is important to be clear: not all patients with Type 2 diabetes will achieve remission on semaglutide. For patients with long-standing diabetes, significant pancreatic damage, or multiple complicating factors, remission may not be realistic. The more certain outcome is meaningful improvement in blood sugar control that reduces complication risk — which is itself a profoundly valuable result.

How does semaglutide compare to other diabetes medications?

Indian patients with Type 2 diabetes are most commonly prescribed metformin, sulfonylureas (like glipizide or glimepiride), or insulin. Here is how semaglutide compares:

For patients who are overweight and need both glucose control and weight management, semaglutide's profile is compelling — particularly the combination of meaningful HbA1c reduction, significant weight loss, no hypoglycaemia risk, and proven cardiovascular protection.

Who with diabetes qualifies for semaglutide in India?

Adults with Type 2 diabetes who are:

• Inadequately controlled on existing medication (HbA1c above target despite current treatment)

• Overweight or obese (BMI ≥ 23 in Indians)

• At elevated cardiovascular risk

• Seeking to reduce their reliance on insulin or sulfonylureas

Semaglutide is not appropriate for Type 1 diabetes, which is caused by autoimmune destruction of insulin-producing cells. It is also not a substitute for insulin in patients who require it — but it may allow some patients to reduce their insulin dose under medical supervision.

Important considerations for diabetic patients starting semaglutide

Medication adjustments may be needed. If you are on a sulfonylurea, your doctor may reduce the dose when starting semaglutide — because the combination can cause low blood sugar. If you are on insulin, the dose may need to be reviewed as blood sugar improves. Do not adjust your existing medications without guidance.

Monitor blood sugar during adjustment. In the first weeks of starting or escalating semaglutide, blood sugar typically improves. Patients on insulin or sulfonylureas should monitor more frequently during this period.

Share your full medication list. Your ZIVOLABS doctor needs to know every diabetes medication you currently take to advise on adjustments safely.

Frequently asked questions

Can semaglutide replace metformin? Generally no — not as an either/or substitution. Metformin remains a first-line medication for Type 2 diabetes in most guidelines. Semaglutide is typically added to existing treatment rather than replacing it. Your doctor will review your specific situation.

I have been on insulin for years. Can I switch to semaglutide? This depends on how much insulin your body still produces. Semaglutide works by stimulating your own insulin release — if your pancreas has very limited remaining function, it may not be sufficient on its own. This is a detailed clinical question that your ZIVOLABS doctor will assess based on your history and bloodwork.

Will my HbA1c improve before I lose weight? Yes — some improvement in HbA1c begins quickly, even before significant weight loss occurs, because of semaglutide's direct effect on insulin release and glucagon suppression. Weight loss amplifies the improvement over time.

Can I use semaglutide if I have diabetic kidney disease? Mild to moderate chronic kidney disease is not a contraindication. Severe kidney disease (eGFR below 15) requires careful assessment. Your ZIVOLABS doctor will review your kidney function before prescribing.

Start managing both — with one medication

A ZIVOLABS doctor can assess whether semaglutide is appropriate for your diabetes management — and review your current medications to plan the transition safely.

[Start your free health assessment →]

This article is for informational purposes only and does not constitute medical advice. Diabetes management requires individualised medical supervision. Do not adjust your existing diabetes medications without guidance from your doctor. Individual results may vary.